ALPHA-TOCOPHEROL, BETA-CAROTENE LUNG CANCER PREVENTION STUDY

α-生育酚、β-胡萝卜素预防肺癌研究（ATBC 研究）正在研究每日口服α-生育酚（50 mg）的功效 和β-胡萝卜素（20 mg），在一项双盲、随机2x2析因研究中， 在50-69岁男性中预防肺癌的设计试验 吸烟者。 该项目是基于实验和 流行病学研究表明， 这些代理人。 招募发生在1985年至1988年之间，审判将 1993年，平均随访6年以上。 邮政调查 2009年，对291，000名男性进行了潜在试验参与者的筛选， 芬兰南部，76%的人回答。 我们邀请了那些愿意 参与（43，000）13个研究诊所之一，超过29，000人 随机分配到研究中。 每天服用一粒胶囊的依从性 仍然很高（平均97%），辍学率平均低于 每年6%。 降低活性药物组的肺癌发病率 是主要研究目标;其他癌症发生率的差异 也将进行评估。 为支持试验， 还完成了包括可行性研究，验证研究 饮食问卷调查，皮肤变黄和血清水平评估 在β-胡萝卜素给药后。 这项试验是与监测项目合作进行的 癌症预防和控制司和国家公众 芬兰卫生研究所。

The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study (ATBC Study) is investigating the efficacy of daily oral alpha-tocopherol (50 mg) and beta-carotene (20 mg) in a double-blind, randomized 2x2 factorial design trial aimed at preventing lung cancer among 50-69 year old male cigarette smokers. The project is based on experimental and epidemiological research which demonstrates a potential preventive role for these agents. Recruitment took place between 1985-1988, and the trial will end in 1993 after an average follow-up of over 6 years. A postal survey screening for potential trial participants was sent to 291,000 men in southern Finland, and 76% responded. We invited the smokers willing to participate (43,000) to one of 13 study clinics, and over 29,000 were randomized into the study. Compliance to the one capsule daily regimen has remained very high (97% average), and the dropout rate averages less than 6% per year. Reduction of lung cancer incidence in the active agent groups is the primary study goal; differences in the occurrence of other cancers will also be evaluated. Several pilot studies in support of the trial have also been completed including a feasibility study, validation of study dietary questionnaires, and evaluation of skin yellowing and serum levels following beta-carotene administration. This trial is being conducted collaboratively with the Surveillance Program of the Division of Cancer Prevention and Control and the National Public Health Institute of Finland.